Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064485 | 0.88 | AGXT (0.44) | HDAC3AGXTESR1ESR2MAOB | |
| SCHEMBL3512251 | 0.80 | KDM4A (0.54) | AGXTNQO2MAOBKDM4ALOXL2 | |
| SCHEMBL1295500 | 0.76 | EPHX2 (0.47) | AGXTNQO2ESR1ESR2MAOB | |
| SCHEMBL7328495 | 0.74 | CTSK (0.50) | HDAC3MEN1NPC1GAARAB9A | |
| SCHEMBL7104950 | 0.74 | RAB9A (0.42) | AGXTMAOBKDM4ALOXL2MEN1 | |
| SCHEMBL8579944 | 0.74 | PIN1 (0.60) | PSMB5 | |
| SCHEMBL5986229 | 0.74 | PPIA (0.45) | AGXTMAOBKDM4ALOXL2MEN1 | |
| SCHEMBL2628545 | 0.74 | PIN1 (0.60) | PSMB5 | |
| SCHEMBL4499441 | 0.73 | MTNR1A (0.53) | ESR1ESR2MAOBLOXL2MEN1 | |
| SCHEMBL7106927 | 0.72 | MAOB (0.43) | MAOBMEN1NPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153571-A1 | Method and composition for the treatment of pain | ASTRAZENECA AB (SE) | 2003-08-14 | — | — | US | disclosed |
| EP-1244453-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047524-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153571-A1 | Method and composition for the treatment of pain | OPRK1, ACHE, OPRL1 | HDAC3 1426/4885AGXT 2663/4885NQO2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.